SAB Bio Secures $85M to Advance Novel Type 1 Diabetes Therapy

NEW YORK, NY – March 18, 2026 – SAB Biotherapeutics has announced the pricing of a significant $85 million public offering, a critical financial maneuver designed to propel its lead drug candidate for Type 1 Diabetes (T1D) through late-stage clinical trials. The move signals strong investor confidence in the company's novel approach to treating autoimmune diseases and provides a substantial runway to advance its flagship program.

The clinical-stage biopharmaceutical company, traded on Nasdaq under the ticker SABS, priced 19,324,677 shares of its common stock at $3.85 per share. The offering also includes pre-funded warrants for an additional 2,753,246 shares, bringing the total gross proceeds to approximately $85 million before deductions.

A Strategic Capital Infusion

The financing, managed by a formidable syndicate of investment banks including Jefferies, UBS Investment Bank, Citigroup, and Barclays, is more than just a number on a balance sheet. It represents a strategic lifeline that extends the company's operational capacity well into the future. According to recent financial disclosures, SAB Biotherapeutics has been operating with a quarterly cash burn rate of approximately $20 million, driven largely by escalating research and development costs.

This $85 million infusion, layered on top of a previous $175 million private placement in July 2025, solidifies the company’s financial footing. The combined capital is expected to comfortably fund operations for at least the next two years, a crucial period as its lead candidate, SAB-142, progresses through the costly and complex phases of clinical development. While the offering introduces significant dilution for existing shareholders, with the new shares representing roughly a 29% increase in the total shares outstanding, the market often views such moves as a necessary evil for clinical-stage biotech firms. The capital is essential to de-risk the science and move a potential blockbuster drug closer to regulatory approval and commercialization.

The involvement of top-tier underwriters is often interpreted by the market as a vote of confidence in a company's technology and management. This capital raise allows SAB Biotherapeutics to focus squarely on execution, minimizing financial uncertainty as it navigates the regulatory pathway for SAB-142.

Advancing the Frontier of T1D Treatment

The primary beneficiary of this new funding is SAB-142, a fully human anti-thymocyte immunoglobulin (hATG) aimed at fundamentally altering the course of Type 1 Diabetes. Unlike current treatments that primarily focus on managing blood sugar levels through insulin replacement, SAB-142 is a disease-modifying therapeutic. Its goal is to intervene in the autoimmune process itself, potentially delaying the onset of Stage 3 T1D and preserving the patient's own insulin-producing beta cells.

The drug is currently being evaluated in a pivotal Phase 2b clinical trial named SAFEGUARD. This registrational study is enrolling newly diagnosed Stage 3 T1D patients across sites in the United States, Australia, and New Zealand. The company has stated that enrollment is on track to be completed by the end of 2026, with crucial topline data expected in the second half of 2027.

Optimism for the trial is bolstered by positive Phase 1 data reported in late 2025. The initial study demonstrated a favorable safety profile, with SAB-142 showing low immunogenicity and no signs of causing serum sickness—a potential side effect of older, animal-derived antibody therapies. The data confirmed that the drug successfully engaged its intended target, a key indicator of its pharmacodynamic activity. This successful capital raise ensures that the SAFEGUARD study can proceed without financial interruption, bringing a potentially transformative therapy one step closer to the millions of people living with T1D.

The Science Behind the Investment

Underpinning the investor enthusiasm for SAB Biotherapeutics is its proprietary and groundbreaking technology platform. The company has pioneered the use of transchromosomic cattle (Tc-Bovine) to produce fully human polyclonal antibodies. This unique biomanufacturing system essentially turns these genetically engineered animals into living bioreactors capable of generating a robust and diverse immune response to a specific pathogen or antigen.

The process involves introducing human artificial chromosomes into the cattle, enabling them to produce vast quantities of highly potent, fully human immunoglobulin G (hIgG) antibodies when challenged with a target antigen. This platform circumvents the need for human donors or convalescent plasma, offering a scalable, consistent, and on-demand source of therapeutic antibodies.

For SAB-142, the Tc-Bovine are immunized to generate antibodies that target the human T-cells responsible for the autoimmune attack in T1D. The resulting product is a polyclonal antibody therapy, meaning it contains a diverse collection of antibodies that can recognize and act on multiple targets, potentially offering a more potent and durable effect than single-target monoclonal antibodies. This platform technology is not limited to T1D; it holds the potential to generate novel therapies for a wide array of other autoimmune and infectious diseases, representing a significant long-term value proposition for the company beyond its lead candidate.

Market Dynamics and Investor Outlook

For a clinical-stage company like SAB Biotherapeutics, the path to success is paved with scientific milestones and strategic financing. This public offering is a textbook example of the latter, securing the necessary capital to pursue the former. The previous $175 million private placement, which included the strategic investor Sanofi, had already established a strong foundation of support. This follow-on public offering further broadens the company’s investor base and enhances its visibility in the public markets.

Investors and analysts will now be keenly focused on the company's execution. The primary catalysts on the horizon are the completion of enrollment for the SAFEGUARD trial by the end of this year and the subsequent release of topline data in 2027. A positive outcome from this trial could be a major inflection point for the company, validating both SAB-142 as a T1D therapy and the underlying Tc-Bovine platform as a whole.

While the dilution from the offering is a tangible short-term cost, investors are betting that the long-term reward of a successful T1D drug will far outweigh it. The capital provides the fuel, but the journey ahead will be defined by the rigor of the science and the results of the clinical trials. With its financial future secured for the time being, SAB Biotherapeutics is now positioned to fully concentrate on its mission to change the treatment paradigm for Type 1 Diabetes.